Nicox maintains its PEA-PME status for 2026

Nicox, an international specialist in ophthalmology, has confirmed its eligibility for the French PEA-PME investment scheme for 2026. This announcement, published on February 12, 2026, in Sophia Antipolis, guarantees that investors can continue to include Nicox shares in their PEA-PME accounts. The conditions required by the French Monetary and Financial Code have been met, allowing shareholders to benefit from the tax advantages associated with this scheme. Nicox, listed on Euronext Growth Paris, is thus continuing its development while remaining accessible to investors interested in small and mid-cap stocks, strengthening its position on the stock market.